Related Experiment Video

Updated: Jul 5, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

Clinical applications of somatostatin analogs

S W Lamberts1, E P Krenning, J G Klijn

  • 1Department of Medicine, Erasmus University, Rotterdam, The Netherlands.

Trends in Endocrinology and Metabolism: TEM
|January 1, 1990
PubMed

Insights

Sandostatin, a somatostatin analog, treats specific tumors. Researchers are exploring its use with radioactive iodine (123I) to detect other somatostatin receptor-positive tumors in humans.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Endocrinology

Background:

  • The somatostatin analog Sandostatin effectively treats metastatic endocrine pancreatic tumors, carcinoids, and acromegaly.
  • Somatostatin receptors are expressed on various human tumors beyond these primary indications.

Purpose of the Study:

  • To investigate the potential of using a radiolabeled somatostatin analog for tumor imaging.
  • To demonstrate the feasibility of visualizing somatostatin receptor-positive tumors using (123)I-coupled somatostatin analogs.

Main Methods:

  • Administration of (123)I-coupled somatostatin analog.
  • Imaging of somatostatin receptor-positive tumors.

Main Results:

  • Successful demonstration of tumors expressing somatostatin receptors.
  • Potential for diagnostic imaging of a broader range of human tumors.

Conclusions:

  • Radiolabeled somatostatin analogs offer a promising method for detecting various human tumors.
  • This approach expands the diagnostic utility of somatostatin analogs in oncology and nuclear medicine.

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Somatosensation01:33

Somatosensation

The somatosensory system relays sensory information from the skin, mucous membranes, limbs, and joints. Somatosensation is more familiarly known as the sense of touch. A typical somatosensory pathway includes three types of long neurons: primary, secondary, and tertiary. Primary neurons have cell bodies located near the spinal cord in groups of neurons called dorsal root ganglia. The sensory neurons of ganglia innervate designated areas of skin called dermatomes.
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...